Nabriva Therapeutics plc Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2015 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Nabriva Therapeutics plc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2015 to Q2 2023.
  • Nabriva Therapeutics plc Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2023 was -$12.1M, a 8.92% decline year-over-year.
  • Nabriva Therapeutics plc Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2023 was -$55.1M, a 18.1% decline year-over-year.
  • Nabriva Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2022 was -$57.2M, a 15.6% decline from 2021.
  • Nabriva Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2021 was -$49.5M, a 28.8% increase from 2020.
  • Nabriva Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2020 was -$69.5M, a 16% increase from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 -$55.1M -$12.1M -$988K -8.92% Apr 1, 2023 Jun 30, 2023 10-Q 2023-10-19
Q1 2023 -$54.1M -$8.7M +$3.12M +26.4% Jan 1, 2023 Mar 31, 2023 10-Q 2023-10-19
Q4 2022 -$57.2M -$22.8M -$9.72M -74.4% Oct 1, 2022 Dec 31, 2022 10-K 2023-04-17
Q3 2022 -$47.5M -$11.5M -$862K -8.09% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-10
Q2 2022 -$46.6M -$11.1M +$680K +5.79% Apr 1, 2022 Jun 30, 2022 10-Q 2023-10-19
Q1 2022 -$47.3M -$11.8M +$2.16M +15.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-10-19
Q4 2021 -$49.5M -$13.1M +$4.77M +26.7% Oct 1, 2021 Dec 31, 2021 10-K 2023-04-17
Q3 2021 -$54.2M -$10.7M +$2.3M +17.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$56.5M -$11.8M +$3.69M +23.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$60.2M -$14M +$9.28M +39.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$69.5M -$17.8M +$5.21M +22.6% Oct 1, 2020 Dec 31, 2020 10-K 2023-04-17
Q3 2020 -$74.7M -$13M +$4.84M +27.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$79.5M -$15.4M +$6.27M +28.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-09
Q1 2020 -$85.8M -$23.3M -$3.04M -15% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-09
Q4 2019 -$82.8M -$23M +$7.78M +25.2% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-12
Q3 2019 -$90.5M -$17.8M +$35M +66.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$126M -$21.7M -$3.92M -22% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-05
Q1 2019 -$122M -$20.2M -$6.88M -51.5% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-05
Q4 2018 -$115M -$30.8M -$8.56M -38.5% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$106M -$52.8M -$30.6M -137% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 -$75.7M -$17.8M -$3.19M -21.8% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 -$72.5M -$13.3M +$1.88M +12.4% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 -$74.4M -$22.3M -$7.08M -46.6% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 -$67.3M -$22.3M -$8.27M -59.1% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-12
Q2 2017 -$59M -$14.6M -$2.5M -20.6% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-12
Q1 2017 -$56.5M -$15.2M -$1.62M -11.9% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-12
Q4 2016 -$54.9M -$15.2M -$7.22M -90.7% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-16
Q3 2016 -$47.7M -$14M -$5.58M -66.3% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-16
Q2 2016 -$42.1M -$12.1M +$12.4M +50.6% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-16
Q1 2016 -$54.5M -$13.6M -$7.54M -124% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-16
Q4 2015 -$47M -$7.97M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-24
Q3 2015 -$8.42M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-24
Q2 2015 -$24.5M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-24
Q1 2015 -$6.06M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.